Figure 3. Kaplan-Meier analysis for progression-free survival (A) and overall survival (B) according to the chemotherapy regimen just prior nivolumab in patients who achieved disease control by the chemotherapy just prior nivolumab. p-Values were calculated with the log-rank test. RAM+PTX, ramucirumab plus paclitaxel; IRI, irinotecan monotherapy; PTX, paclitaxel monotherapy; nabPTX, nanoparticle albumin-bound paclitaxel monotherapy; PFS, progression free survival; OS, overall survival; CI, confidence interval.